Literature DB >> 17120464

Immunological tolerance and autoimmunity.

Sergio Romagnani1.   

Abstract

Immunological tolerance is a complex series of mechanisms that impair the immune system to mount responses against self antigens. Central tolerance occurs when immature lymphocytes encounter self antigens in the primary lymphoid organs, and consequently they die or become unreactive. Peripheral tolerance occurs when mature lymphocytes, escaped from negative selection during ontogeny, encounter self antigens in secondary lymphoid organs and undergo anergy, deletion or suppression. A heterogeneous family of T regulatory cells has recently been identified, which have been found to play an important role in suppressing immune responses against self. Failure or breakdown of immunological tolerance results in autoimmunity and autoimmune diseases. Such events are related to both genetic and environmental factors, the latter being mainly represented by infections. Infectious agents can indeed promote autoimmune responses either by inducing tissue inflammation and therefore an unintended bystander activation of autoreactive T cells, or by promoting T cell responses to microbial epitopes that cross react against self peptides.

Entities:  

Mesh:

Year:  2006        PMID: 17120464     DOI: 10.1007/bf02934736

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  47 in total

Review 1.  Natural regulatory T cells and self-tolerance.

Authors:  Ronald H Schwartz
Journal:  Nat Immunol       Date:  2005-04       Impact factor: 25.606

2.  The IL-23/IL-17 axis in inflammation.

Authors:  Yoichiro Iwakura; Harumichi Ishigame
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

3.  Immunology: what does it mean to be just 17?

Authors:  Cristina M Tato; John J O'Shea
Journal:  Nature       Date:  2006-05-11       Impact factor: 49.962

4.  CD28 engagement and proinflammatory cytokines contribute to T cell expansion and long-term survival in vivo.

Authors:  A T Vella; T Mitchell; B Groth; P S Linsley; J M Green; C B Thompson; J W Kappler; P Marrack
Journal:  J Immunol       Date:  1997-05-15       Impact factor: 5.422

5.  Genetic and physical mapping of the Lps locus: identification of the toll-4 receptor as a candidate gene in the critical region.

Authors:  A Poltorak; I Smirnova; X He; M Y Liu; C Van Huffel; O McNally; D Birdwell; E Alejos; M Silva; X Du; P Thompson; E K Chan; J Ledesma; B Roe; S Clifton; S N Vogel; B Beutler
Journal:  Blood Cells Mol Dis       Date:  1998-09       Impact factor: 3.039

Review 6.  Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype.

Authors:  Austen Worth; Adrian J Thrasher; H Bobby Gaspar
Journal:  Br J Haematol       Date:  2006-04       Impact factor: 6.998

Review 7.  Bone marrow transplantation: a new strategy for intractable diseases.

Authors:  Susumu Ikehara
Journal:  Drugs Today (Barc)       Date:  2002-02       Impact factor: 2.245

8.  Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis.

Authors:  D M Gross; T Forsthuber; M Tary-Lehmann; C Etling; K Ito; Z A Nagy; J A Field; A C Steere; B T Huber
Journal:  Science       Date:  1998-07-31       Impact factor: 47.728

Review 9.  Lymphokine production by human T cells in disease states.

Authors:  S Romagnani
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

10.  Molecular mimicry between Helicobacter pylori antigens and H+, K+ --adenosine triphosphatase in human gastric autoimmunity.

Authors:  Amedeo Amedei; Mathijs P Bergman; Ben J Appelmelk; Annalisa Azzurri; Marisa Benagiano; Carlo Tamburini; Ruurd van der Zee; John L Telford; Christina M J E Vandenbroucke-Grauls; Mario M D'Elios; Gianfranco Del Prete
Journal:  J Exp Med       Date:  2003-10-20       Impact factor: 14.307

View more
  15 in total

Review 1.  The role of lymphocytes in the development and treatment of alopecia areata.

Authors:  Hongwei Guo; Yabin Cheng; Jerry Shapiro; Kevin McElwee
Journal:  Expert Rev Clin Immunol       Date:  2015-09-07       Impact factor: 4.473

Review 2.  The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases.

Authors:  Giuseppe Murdaca; Barbara Maria Colombo; Francesco Puppo
Journal:  Intern Emerg Med       Date:  2011-01-22       Impact factor: 3.397

3.  H-ferritin-nanocaged doxorubicin nanoparticles specifically target and kill tumors with a single-dose injection.

Authors:  Minmin Liang; Kelong Fan; Meng Zhou; Demin Duan; Jiyan Zheng; Dongling Yang; Jing Feng; Xiyun Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-29       Impact factor: 11.205

4.  Characterization of human invariant natural killer T cells expressing FoxP3.

Authors:  Péter Engelmann; Klára Farkas; János Kis; Geoffrey Richman; Zhaoyun Zhang; Chong Wee Liew; Maciej Borowiec; Monika A Niewczas; Heyam Jalahej; Tihamér Orbán
Journal:  Int Immunol       Date:  2011-06-27       Impact factor: 4.823

5.  A tale of two STAT6 knock out mice in the induction of experimental autoimmune encephalomyelitis.

Authors:  Yongmei Wang; J T Evans; Frederick Rodriguez; Patrick Fields; Cynthia Mueller; Tanuja Chitnis; Samia J Khoury; Margaret S Bynoe
Journal:  J Neuroimmunol       Date:  2008-12-18       Impact factor: 3.478

6.  Chemoimmunotherapy of chronic hepatitis B virus infection in the woodchuck model overcomes immunologic tolerance and restores T-cell responses to pre-S and S regions of the viral envelope protein.

Authors:  Stephan Menne; Bud C Tennant; John L Gerin; Paul J Cote
Journal:  J Virol       Date:  2007-07-25       Impact factor: 5.103

7.  Tolerization with Hsp65 induces protection against adjuvant-induced arthritis by modulating the antigen-directed interferon-gamma, interleukin-17, and antibody responses.

Authors:  Shailesh R Satpute; Rajesh Rajaiah; Swamy K Polumuri; Kamal D Moudgil
Journal:  Arthritis Rheum       Date:  2009-01

Review 8.  Infliximab-related hepatitis: discussion of a case and review of the literature.

Authors:  Stefano Mancini; Elisa Amorotti; Sarah Vecchio; Maurizio Ponz de Leon; Luca Roncucci
Journal:  Intern Emerg Med       Date:  2010-01-27       Impact factor: 3.397

9.  Immune Checkpoint-Bioengineered Beta Cell Vaccine Reverses Early-Onset Type 1 Diabetes.

Authors:  Kin Man Au; Yusra Medik; Qi Ke; Roland Tisch; Andrew Z Wang
Journal:  Adv Mater       Date:  2021-05-08       Impact factor: 32.086

10.  The relative merits of therapies being developed to tackle inappropriate ('self'-directed) complement activation.

Authors:  Samuel Antwi-Baffour; Ransford Kyeremeh; Jonathan Kofi Adjei; Claudia Aryeh; George Kpentey
Journal:  Auto Immun Highlights       Date:  2016-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.